A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C

Thúy, Phạm Thị Thu; Bunchorntavakul, Chalermrat; Dat, Ho Tan; Reddy, K. Rajender

doi:10.1016/j.jhep.2011.12.020

Cited by 35 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon comparing RCT versus non-RCT, we observed a pooled SVR rate of 70% (95% CI: 0.64-0.77) in 2 RCTs [20,27], compared with 83% (95% CI: 0.79-0.86) in 11 non-RCTs. This finding was statistically significant (p = 0.032).…”

Section: Resultsmentioning

confidence: 90%

“…The modified process employed for study search and selection is summarized in figure 1. After the titles were screened and abstracts read, 193 studies were removed based on exclusion criteria and 14 potentially eligible articles included [17,18,19,20,21,22,23,24,25,26,27,28,29,30]. Among these studies, some studies were only included on the treatment efficacy of PEG-IFN+RBV for HCV-6 in a previous study [31].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Thông¹,

Poovorawan²,

Tangkijvanich

et al. 2015

Intervirology

View full text Add to dashboard Cite

Objectives: We conducted a systematic review and meta-analysis of the influence of host and viral factors on the sustained virologic response (SVR) in hepatitis C virus genotype 6 (HCV-6) patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Methods: Data were retrieved fromMedline, Embase, PubMed and the Cochrane Library for ‘genotype 6' studies published up to December 2014 and for abstracts from international scientific meetings. Inclusion criteria were efficacy of PEG-IFN+RBV based on SVR, 24- or 48-week therapy and treatment-naïve patients. Patients with hepatitis B, D and E and HIV coinfection or another concurrent liver disease were excluded. Pooled standard difference, odds ratio and confidence intervals (CIs) were calculated using a random-effect model with STATA 11. Results: Fourteen studies were included in the meta-analysis. The pooled SVR rate was 80% (95% CI: 0.78-0.83, p < 0.0001; I² = 71.2%). SVR of the PEG-IFN+RBV-treated HCV-6 patients was markedly higher than that of HCV-1 patients (80.1 vs. 55.3%). The SVR rate was significantly higher for the 48- than the 24-week treatment, but not different among HCV-infected patients with rs12979860 and ss469415590 polymorphisms of the ILFN4 gene (80.6% CC vs. 66.7% non-CC, p = 0.593; 81.1% TT/TT vs. 60% non-TT/TT, p = 0.288). Gender and type of PEG-IFN did not affect SVR rates. Conclusions: Treatment outcomes for HCV-6 patients are superior to those for HCV-1 patients and comparable to those of HCV-2 and HCV-3 patients, especially at 48 weeks. The level of fibrosis affects treatment outcome, but SVR rates are not significantly different between genders. IL28B and IFNL4 polymorphisms are not significantly associated with HCV-6 treatment outcome.

show abstract

Section: Resultsmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Thông¹,

Poovorawan²,

Tangkijvanich

et al. 2015

Intervirology

View full text Add to dashboard Cite

show abstract

“…Moreover, genotype 6 is also often seen in special populations, such as patients with thalassemia major and intravenous drug users (12,13). Importantly, patients with genotype 6 respond better to PEG-IFN and RBV treatment than do patients with genotype 1, and it may be practical to shorten the treatment duration from 48 weeks to 24 weeks in order to help reduce the occurrence of adverse events and limit the disease burden (14). Recent studies have shown that patients with genotype 6 respond well to DAAs, such as simeprevir and sofosbuvir (15)(16)(17).…”

Section: H Epatitis C Virus (Hcv) Infects 170 Million People Worldwidementioning

confidence: 99%

“…From another point of view, most patients with genotype 6 live in low-income countries and may not be able to afford the high cost of DAAs. Thus, the standard of care, i.e., PEG-IFN and RBV, remains the most common and cost-effective option (14). Therefore, the accurate identification of patients with genotype 6 is still important, even in the era of DAAs.…”

Section: H Epatitis C Virus (Hcv) Infects 170 Million People Worldwidementioning

confidence: 99%

“…After the update of the readout software, 19 samples previously identified as a mixture of genotypes 1 and 6 were correctly genotyped as single genotype 6 samples. This difference is important, because patients with genotype 6 are expected to achieve high SVR even with a shorter course of treatment (24 weeks) with PEG-IFN and RBV, particularly for those who had undetectable HCV RNA at week 4 (14). If a patient is misdiagnosed as having a genotype 1 and 6 coinfection, physicians will have to treat the patient as though he or she has an infection with genotype 1.…”

Section: Comparison Of Lipa and Realtime For Detecting Hcv Genotypementioning

confidence: 99%

See 1 more Smart Citation

Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II Assay for Detecting Hepatitis C Virus Genotype 6

Yang

et al. 2014

J Clin Microbiol

View full text Add to dashboard Cite

The Versant HCV genotype 2.0 assay (line probe assay [LiPA] 2.0), based on reverse hybridization, and the Abbott Realtime HCV genotype II assay (Realtime II), based on genotype-specific real-time PCR, have been widely used to analyze hepatitis C virus (HCV) genotypes. However, their performances for detecting HCV genotype 6 infections have not been well studied. Here, we analyzed genotype 6 in 63 samples from the China HCV Genotyping Study that were originally identified as genotype 6 using the LiPA 2.0. The genotyping results were confirmed by nonstructural 5B (NS5B) or core sequence phylogenetic analysis. A total of 57 samples were confirmed to be genotype 6 (51 genotype 6a, 5 genotype 6n, and 1 genotype 6e). Four samples identified as a mixture of genotypes 6 and 4 by the LiPA 2.0 were confirmed to be genotype 3b. The remaining two samples classified as genotype 6 by the LiPA 2.0 were confirmed to be genotype 1b, which were intergenotypic recombinants and excluded from further comparison. In 57 genotype 6 samples detected using the Realtime II version 2.00 assay, 47 genotype 6a samples were identified as genotype 6, one 6e sample was misclassified as genotype 1, and four 6a and five 6n samples yielded indeterminate results. Nine nucleotide profiles in the 5= untranslated region affected the performances of both assays. Therefore, our analysis shows that both assays have limitations in identifying HCV genotype 6. The LiPA 2.0 cannot distinguish some 3b samples from genotype 6 samples. The Realtime II assay fails to identify some 6a and all non-6a subtypes, and it misclassifies genotype 6e as genotype 1.

show abstract

Hepatitis C Virus Infection

Tai

Chung

2015

Yamada' S Textbook of Gastroenterology

View full text Add to dashboard Cite

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C

Cited by 35 publications

References 26 publications

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II Assay for Detecting Hepatitis C Virus Genotype 6

Hepatitis C Virus Infection

Contact Info

Product

Resources

About